PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Conclusion: MM cells colonized to bones activate osteolysis, changes of fat genes compatible with fat browning; characterics of cachexia. Cachexia in MM may be attributed to other factors in addition to PTHrP. The backbone anti-myeloma drugs, Lenalidomide and Bortezomib, and the antiresorptive Zoledronic acid have limited effect on tumor-induced fat browning. Bone+MM coculture allows concurrent assessment of tumor, bone and fat changes, and can be applied to studies of novel agents to combat cachexia in myeloma.DisclosuresSuvannasankha: Glaxo Smith Klein: Research Funding; Janssen: Research Funding; Celgene: Honoraria; Amgen: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Suvannasankha, A., Crean, C., Ochoa, I. C., Roodman, G. D., Chirgwin, J. Tags: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III Source Type: research